=Molecular Templates (MTEM) : Phase 1 expansion study of MT-3724

Molecular Templates announced the dosing of the first patient in a Phase 1 expansion study of MT-3724, a first-generation ETB that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias. 

Co states, "Strong evidence of anti-tumor activity in heavily pre-treated patients has been observed in Part 1 of the study."

• The MTD was identified as 75 mcg/kg and this was supported by a dose-dependent clearance of CD20+ peripheral B cells, which is an acknowledged surrogate marker of efficacy.
• Establishment of the MTD has triggered initiation of Part 2 of the study, in which relapsed or refractory DLBCL patients without high serum levels of Rituxan will be treated with MT-3724 as a monotherapy at the MTD dose.
• The study has been designed to enroll up to 40 patients in total.